31 Aug
2021

PTAB proceedings are a vital tool in the biologics space, despite low usage rates

The latest USPTO figures show declining PTAB petitions and institutions in the life sciences. However, for biosimilars, administrative challenges are fulfilling a key strategic purpose

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth